Answer to the question
TherapeuticsMD reported earnings of $0.05 per share on both a basic and a diluted basis for the quarter ended June 30 2025. In other words, the diluted EPS is identical to the basic EPS—there is no dilution effect from stock options, convertible securities, or other potentially dilutive instruments in this period.
Trading implications
Because the basic and diluted EPS are the same, the market’s perception of earnings quality isn’t clouded by dilution; the $0.05 figure reflects the true earnings attributable to each outstanding share. This clean earnings metric, coupled with the swing from a prior loss to a modest profit, suggests a turnaround signal that could attract short‑term speculative interest. However, the absolute EPS level remains low, and the company’s royalty‑based business model still carries sector‑specific risk (e.g., drug pipeline outcomes, regulatory changes).
From a technical standpoint, TXMD’s price has likely been reacting to the earnings beat and the positive EPS shift. If the stock is holding above its recent 20‑day moving average and showing bullish momentum (e.g., higher highs and higher lows on the daily chart), a short‑to‑mid‑term long position could be justified, targeting a bounce back toward the prior resistance level (often the prior quarter’s high). Conversely, if the price is still below the 20‑day average or showing weak volume, it may be prudent to stay on the sidelines until the next earnings cycle confirms sustained profitability.
Bottom line: The basic and diluted EPS are equal at $0.05, indicating no dilution impact this quarter. Traders can view the earnings improvement as a modest, but clean, catalyst—potentially supporting a short‑term upside if technicals are favorable, while remaining cautious of the company’s low earnings base and sector‑specific fundamentals.